# Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia

> **NCT03686345** · PHASE2 · TERMINATED · sponsor: **Niguarda Hospital** · enrollment: 34 (actual)

## Conditions studied

- Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

## Interventions

- **DRUG:** Midostaurin

## Key facts

- **NCT ID:** NCT03686345
- **Lead sponsor:** Niguarda Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** didn't reach the primary endpoint
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03686345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03686345, "Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03686345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*